Investing Ideas
/
Brazilian Pharmaceuticals & Biotech Undervalued based on future growth

Brazilian Pharmaceuticals & Biotech Undervalued based on future growth

Name: Financial Insights Based on S&P Global Market Intelligence
Creator: Simply Wall St Pty Ltd
License: https://www.spglobal.com/content/dam/spglobal/corporate/en/documents/secure/MI-FastTrack-Terms-and-Conditions-July-2023.pdf

Results

0 new

Companies which can be considered undervalued when accounting for expected future growth (PEG under 0.8)

1 companies

Hypera

Market Cap: R$17.6b

Operates as a pharmaceutical company in Brazil.

HYPE3

R$27.80

7.0%

-3.3%